+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying BMS-986515, a healthy donor allogeneic CD19-targeted CAR T cell therapy, to assess its safety, tolerability, best dosing, and early effectiveness in adults with severe, treatment-resistant autoimmune diseases. This phase 1 trial focuses on participants with refractory autoimmune conditions such as systemic lupus erythematosus, inflammatory myopathy, systemic sclerosis, and rheumatoid arthritis who have not responded adequately to standard treatments. Participants receive BMS-986515 along with drugs including fludarabine, cyclophosphamide, and tocilizumab in specified doses given on set days. The study is designed as a single group intervention evaluating the investigational cellular therapys impact and safety profile over time, with close monitoring following the infusion of the CAR T cells. During the trial, participants will undergo extensive safety and response assessments up to 24 months after receiving BMS-986515. Researchers will track adverse events, laboratory results, and signs of disease remission or activity using specific clinical criteria and questionnaires. The study includes long-term follow-up to evaluate ongoing effects and tolerability of the treatment.

Age: 18Years +All GendersPhase 1
28 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of Afimkibart also known as RO7790121 in adults with moderate to severe rheumatoid arthritis RA who have not responded well or cannot tolerate tumor necrosis factor TNF andor Janus kinase JAK inhibitors. This Phase II, multicenter, randomized, double-blind, placebo-controlled study aims to compare Afimkibart with placebo in this group to better understand its impact on disease activity. Participants will receive either Afimkibart or a placebo through subcutaneous under the skin injections. The study includes two experimental groups receiving Afimkibart and one placebo group, all administered by injection. Treatment and assessments occur over several weeks, with key evaluations at Week 14 and Week 24 to measure changes in disease activity and response. During the study, participants will undergo various assessments including joint counts, patient and physician global assessments, laboratory tests for inflammation markers, and questionnaires on health status and pain. The main outcome is the change in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein DAS28-CRP at Week 14. Safety will be monitored throughout the trial up to Week 38, including tracking adverse events and immune responses to the drug. Participants can expect regular visits for injections and evaluations during this period.

Age: 18Years +All GendersPhase 2
65 locations
A

Actively Recruiting

Researchers are evaluating bimekizumab administered intravenously compared to subcutaneous injection in adults with active psoriatic arthritis or active axial spondyloarthritis. The study aims to show that the intravenous method is not less effective than the subcutaneous method by assessing how the drug moves in the body over time. This is a Phase 1, open-label, randomized, parallel-group study focused on treatment. Participants will receive one of three dosing regimens of bimekizumab during a pharmacokinetics lead-in phase and continue with the same assigned regimen during the treatment period. The dosing regimens include intravenous and subcutaneous administration of bimekizumab at specified times. Subjects are randomized into one of two experimental arms reflecting different intravenous regimens or a third arm receiving the subcutaneous regimen. During the study, participants will be monitored for steady-state trough concentration of the drug at week 16. Safety is assessed by tracking treatment-emergent adverse events, serious adverse events, and any events leading to withdrawal from the study through week 29. The study duration extends to the end of safety follow-up, with regular assessments to evaluate drug levels and participant health under medical supervision.

Age: 18Years +All GendersPhase 1
63 locations
E

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of Afimkibart also called RO7790121 in adults with moderate to severe Rheumatoid Arthritis who have not responded well or are intolerant to tumor necrosis factor TNF andor Janus kinase JAK inhibitors. This study focuses on participants who have already been treated with Afimkibart in earlier clinical trials. The goal is to understand how Afimkibart works over an extended period in this patient group. Participants will receive Afimkibart as a subcutaneous injection according to the study protocol. The study uses a randomized, parallel design with two experimental groups both receiving Afimkibart. The treatment lasts up to six years, allowing researchers to gather long-term data on safety and disease control. There are no placebo or comparator groups in this extension study. During the study, participants will be regularly assessed for adverse events and improvements in Rheumatoid Arthritis symptoms using measures like the American College of Rheumatology improvement criteria and Disease Activity Scores. Blood tests will monitor Afimkibart levels and antibody responses. The study also tracks clinical remission and low disease activity over time. Participants are monitored closely throughout the study to evaluate treatment effects and safety for up to six years.

Age: 18Years +All GendersPhase 2
12 locations
L

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting joints and skin. This Phase 3 study aims to assess the long-term safety, tolerability, and effectiveness of the drug zasocitinib in adults with active PsA. It includes adults who have completed a previous year-long treatment in related parent studies and evaluates continued treatment over an extended period. Participants who previously took zasocitinib will maintain their assigned dose, while those initially on a different treatment will be randomly assigned to one of two doses of zasocitinib, taken once daily as oral tablets. The study treatment phase lasts up to 104 weeks, followed by a 4-week health monitoring period, totaling about 2 years of participation. During the study, participants will be regularly monitored for side effects, vital signs, and lab tests to assess safety. Researchers will also evaluate treatment effectiveness using criteria like the American College of Rheumatology response and skin improvement scores at multiple time points. After treatment, a follow-up period will ensure participants health is observed for any ongoing effects.

Age: 18Years +All GendersPhase 3
78 locations
S

Actively Recruiting

Researchers are evaluating KBP-336, a drug designed to treat knee pain caused by osteoarthritis in people who are also living with obesity. This Phase 2 clinical trial aims to find out if KBP-336 can reduce pain and body weight compared to a placebo, while also assessing its effects on quality of life, metabolism, and safety. The study is sponsored by KeyBioscience AG and focuses on adults aged 45 years and older with diagnosed osteoarthritis of the knee and obesity. Participants in this study will receive weekly subcutaneous injections of KBP-336 or a placebo for six months. The study compares multiple dosages of KBP-336 against placebo, with participants visiting the clinic every two weeks for checkups and tests. Throughout the trial, participants will maintain a diary recording their symptoms and use of any additional pain medications allowed as rescue treatment. During the study, participants will be regularly assessed using several tools, including the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC for pain, stiffness, and function, as well as quality of life questionnaires AQol 8D. Researchers will monitor changes in body weight, pain levels, body composition, bone density, and medication use over 183 days. Safety and well-being will be closely observed through physical exams, vital signs, ECGs, and lab tests, with the total trial duration lasting about six months for each participant.

Age: 45Years +All GendersPhase 2
20 locations
R

Actively Recruiting

Researchers are evaluating the effects of intra-articular injections of Allocetra in people aged 64 and older who have moderate-to-severe primary knee osteoarthritis, a condition where joint cartilage breaks down and causes chronic knee inflammation, pain, and functional issues. This randomized, double-blind, placebo-controlled Phase IIb study compares Allocetra to a placebo to assess its potential benefits. Participants will receive three ultrasound-guided injections directly into the affected knee on Days 0, 14, and 28. Allocetra is a cell-based therapy made from modified allogeneic peripheral blood mononuclear cells designed to influence immune cells in the knee joint. The study includes two groups one receiving Allocetra injections and the other receiving placebo injections. After treatment, participants will be followed for 12 months to monitor outcomes. Throughout the study, participants will undergo assessments including pain and function evaluations using the Western Ontario and McMaster Universities Arthritis Index WOMAC at 3 and 6 months, safety monitoring for six months, and quality of life measurements. Researchers will track daily pain scores and other functional scales to evaluate the treatments impact. The studys total duration from treatment to follow-up is about one year.

Age: 64Years +All GendersPhase 2
17 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.

Age: 12Years - 100YearsAll GendersPhase 3
164 locations

1-10 of 11

1